We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Test Identifies Resistance to Chemotherapy in Esophageal Cancer Patients

By LabMedica International staff writers
Posted on 06 Feb 2014
A proprietary predictive test for esophageal cancer demonstrated strong accuracy and specificity in identifying patients who are likely to have tumors that are extremely resistant to standard presurgical treatment of chemotherapy and radiation.

Approximately 25% of esophageal cancer patients exhibit extreme resistance to standard regimens of chemotherapy and radiation therapy, and therefore do not respond to the presurgical treatment, and can be considered for alternative neoadjuvant therapies or move directly to surgery to remove the tumor.

Cancer Patients Image: Micrograph of an intramucosal esophageal adenocarcinoma, a type of esophageal cancer (Photo courtesy of Nephron).
Cancer Patients Image: Micrograph of an intramucosal esophageal adenocarcinoma, a type of esophageal cancer (Photo courtesy of Nephron).

The test, a three-protein biomarker assay, was discovered by scientists at M.D. Anderson Cancer Center (Houston, TX, USA). Pretreatment tumor biopsies were used to evaluate treatment resistance with this predictive assay. The test reliably differentiates patients who are complete or partial responders to chemotherapy and radiation from those who are nonresponders. The initial, single center validation study of 167 patients demonstrated an accuracy of 92% and specificity of 97%.

In a second, independent, multicenter study, the accuracy was 79% and the specificity was 95% for classifying which patients are likely to be highly resistant to presurgical chemotherapy treatment for esophageal cancer. The predictive algorithm classifies patients as either extreme resistance to chemo-radiation (exCTRT; College of American Pathology Treatment Response Grade 3) or non-extreme resistance to chemo-radiation (non-exCTRT; College of American Pathology Treatment Response Grade 0, 1, or 2).

The test, DecisionDx-EC (Castle Biosciences, Friendswood, TX, USA), uses compartmental localization of the protein biomarkers: nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), Zinc finger protein, glioma-associated oncogene (Gli1) and sonic hedgehog (SHH) in pretreated tumor biopsies to determine a localization index score for each biomarker. This information is then analyzed using a proprietary algorithm to predict exCTRT or non-exCTRT.

Kenneth A. Kesler MD, Professor of Surgery, Thoracic Oncology Program, Indiana University (Indianapolis, IN, USA) said, “Induction chemotherapy and radiation therapy are recommended prior to surgery in most cases. However, induction therapy can result in significant toxicity and will achieve no clinical benefits in up to a quarter of patients. The ability to identify resistance to certain chemotherapy agents allows selection of alternative chemotherapy agents or treatment strategies.” The study was presented at the 2014 Gastrointestinal Cancers Symposium held January 16–18, 2014, in San Francisco, CA, USA).

Related Links:

M.D. Anderson Cancer Center
Castle Biosciences
Indiana University 



Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Thyroxine ELISA
T4 ELISA
New
PSA Test
Human Semen Rapid Test

Latest Pathology News

AI Method Measures Cancer Severity Using Pathology Reports

New Microscopy Method Enables Detailed Whole Brain 3D RNA Analysis

AI Model Identifies Signs of Disease Faster and More Accurately Than Humans